Jeffrey Bedard joins Ethics Talk to discuss his article: "What Should Patients Be Told About Device Representatives’ Roles at the Point of Surgical Care?"
Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
Carmen Black Parker, MD, Amanda Calhoun, MD, MPH, Ambrose H. Wong, MD, MSEd, Larry Davidson, PhD, and Charles Dike, MBChB, MPH
Psychiatric emergencies, coping stress reactions, and iatrogenic injuries are not responded to with the same vigor as acute medical decompensation. That needs to change.
AMA J Ethics. 2020;22(11):E956-964. doi:
10.1001/amajethics.2020.956.
Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.
AMA J Ethics. 2020;22(8):E743-750. doi:
10.1001/amajethics.2020.743.
Dr Travis Rieder discusses his own experiences with opioids and the ethical challenges of “legacy patients,” and Dr Stephanie Zaza, president of the American College of Preventive Medicine, discusses the future of opioid research priorities.
Researchers and clinicians face ethical and policy-based challenges in disclosing, preventing and treating psychosis. Which diagnostic labels should be considered to motivate more effective public and professional dialogue about psychosis risk?
AMA J Ethics. 2016;18(6):624-632. doi:
10.1001/journalofethics.2016.18.6.msoc1-1606.